ArticleHaematologica2024

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia.

Tracy Murphy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.